Breath Therapeutics BV has appointed Melissa Yeager to the newly created position of chief regulatory officer to prepare for the commercialisation of its inhalation therapy for bronchiolitis obliterans. Ms Yeager was previously an independent regulatory consultant. She has also been chief operating officer at Cardeas Pharma Corp and head of regulatory affairs at Gilead Sciences Inc. She holds a bachelor’s degree in human biology from Stanford University and a Juris Doctor degree from Santa Clara University in the US.
Breath Therapeutics announced the appointment on 5 July 2017.
Copyright 2017 Evernow Publishing Ltd